Investment Rating - The report maintains a "BUY" rating for RemeGen, with a revised target price of HK$41.72, down from HK$57.65, indicating a potential upside of 53.7% from the current price of HK$27.15 [5][3]. Core Insights - RemeGen recorded revenue of RMB1.08 billion in FY23, with product sales contributing RMB1.05 billion, reflecting a 42% year-over-year increase. The gross profit margin improved to 76.9% from 63.4% in FY22. However, the company reported a wider attributable net loss of RMB1.51 billion in FY23 compared to RMB999 million in FY22 [3][11]. - The company anticipates a significant ramp-up in sales for FY24, targeting at least a 50% year-over-year increase in product sales, driven by strong performance of RC18 and RC48, an expanded salesforce, and inclusion in numerous top-grade hospitals [3][9]. - RemeGen is progressing with the global development of RC18, with the first stage of its Phase 3 trial completed. The company is considering whether to unblind the study results, which could serve as a catalyst for further development and potential out-licensing deals [3][10]. - The report highlights the potential for overseas business development collaborations, particularly for RC18 and RC88, which has received fast track designation from the FDA. These collaborations are expected to be crucial for RemeGen's growth trajectory [3][10]. Financial Summary - In FY23, RemeGen's revenue was RMB1,076 million, with a gross profit of RMB823 million, resulting in a gross margin of 76.5%. The company incurred operating expenses of RMB2,334 million, leading to an operating loss of RMB1,488 million [11][13]. - For FY24, the revenue is projected to reach RMB1,601 million, with a gross profit of RMB1,225 million, maintaining a gross margin of 76.5% [11][10]. - The net profit for FY24 is expected to be a loss of RMB1,451 million, improving to a loss of RMB1,070 million in FY25, and further narrowing to a loss of RMB362 million in FY26 [11][10].

Investment Rating - The report maintains an "Add" rating for the company [1][2][10]. Core Insights - The company reported a revenue of 1.076 billion RMB in 2023, representing a year-on-year growth of 40.16%. However, it incurred a net loss of 1.511 billion RMB, compared to a loss of 999 million RMB in 2022 [2][6][10]. - Sales of the products Taitasip and Vidisizumab showed steady growth, with successful hospital drug access progress. Taitasip is advancing globally across multiple indications, while Vidisizumab is expanding its indications and showing potential in combination therapies [2][7][8]. - The company has a robust pipeline focused on differentiated antibodies and ADC drugs, with expectations for increased global market potential as indications progress [2][10]. Financial Summary - Revenue for 2023 was 1,076.13 million RMB, with projected revenues of 1,666.88 million RMB, 2,782.65 million RMB, and 3,929.19 million RMB for 2024, 2025, and 2026 respectively, indicating growth rates of 54.90%, 66.94%, and 41.20% [3][11]. - The net profit forecast for 2024-2026 is projected at -1,511.18 million RMB, -1,293.94 million RMB, and -719.15 million RMB, with EPS expected to improve from -2.38 RMB in 2024 to -0.26 RMB in 2026 [3][11]. - The gross margin for 2023 was reported at 77.43%, with a significant increase in R&D expenses to 1.306 billion RMB, reflecting a 33% year-on-year growth [10][11]. Market Data - As of April 2, 2024, the closing price was 27.65 HKD, with a total share capital of 544.33 million shares and a net asset value of 3,437.27 million RMB [4].

股 票 研 究 [Table_industryInfo] 医药 [ Table_Main[荣I Tnaf 昌bol]e 生_Ti物tle]（ 9995） [评Tab级le_：Inv est] 增持 当前价格（港元）： 25.65 业绩符合预期，商业化有望加速兑现 2024.03.29 海 ——荣昌生物2023 年报点评 [ 交Ta易bl数e_M据a rket] 外 丁丹(分析师) 甘坛焕(分析师) 52周内股价区间（港元） 15.22-52.00 当前股本（百万股） 544 公 0755-23976735 021-38675855 当前市值（百万港元） 13,962 司 dingdan@gtjas.com gantanhuan028803@gtjas.com 证书编号 S0880514030001 S0880523080007 （ [ Table_PicQuote] 中 本报告导读： 52周内股价走势图 国 2023年两款药物销售额均超 5亿元，泰它西普MG适应症预计年底提交NDA，RC48 荣昌生物 恒生指数 香 国内外提线临床进展顺利，预计2024年产品收入增速超50%。维持“增持”评级。 10% 摘要： ...

Investment Rating - The report maintains a "Buy" rating for Rongchang Biopharmaceutical (9995 HK) with a target price of HKD 56.00, indicating a potential upside of 106.3% from the current price of HKD 27.15 [1][2][9]. Core Insights - FY23 product revenue showed strong performance with a total revenue of RMB 1.076 billion, representing a year-on-year increase of 40.2%. Product revenue specifically grew by 42.1% to RMB 1.049 billion. The company recorded a net loss of RMB 1.511 billion, which is an increase of 51.3% compared to the previous year [1][4]. - The company expects product sales to grow by over 50% in FY24, targeting more than RMB 1.57 billion in revenue, supported by a stable commercialization team and optimized training [1][2]. - Key R&D and regulatory approval focuses for 2024 include the domestic approval of Taitasip for RA in 2H24, submission of sNDA for MG by year-end, and ongoing Phase III trials for various indications [1][2]. Financial Summary - For FY24, revenue is projected to reach RMB 1.663 billion, with a growth rate of 54.5%. The net loss is expected to narrow to RMB 1.197 billion [4][10]. - The report adjusts sales forecasts for Taitasip and Vidisizumab to RMB 840 million and RMB 820 million respectively for FY24, with further projections for FY25 at RMB 1.25 billion and RMB 1.09 billion [2][7]. - The company’s cash balance at the end of FY23 was RMB 727 million, with bank credit facilities amounting to approximately RMB 4 billion [1][4]. Market Position - Rongchang Biopharmaceutical is positioned within the biotechnology sector, focusing on innovative therapies and has a significant market presence with a market capitalization of approximately HKD 25.37 billion [3][9]. - The report highlights the competitive landscape and the company's strategic focus on expanding its product pipeline and enhancing operational efficiency [1][2].

Financial Performance - The company reported no profit distribution or capital reserve transfer to increase share capital for the fiscal year 2023[5]. - The company reported a 20% increase in revenue year-over-year, reaching $1.5 billion for the fiscal year 2023[15]. - The net profit attributable to shareholders for 2023 was approximately -¥1.51 billion, a significant decrease compared to -¥998.83 million in 2022[22]. - The company's operating revenue for 2023 was approximately ¥1.08 billion, representing a year-over-year increase of 40.26% due to increased sales of Taitasip and Vidisilimab[22]. - The total assets decreased by 8.19% year-over-year to approximately ¥5.53 billion, while the net assets attributable to shareholders decreased by 30.98% to approximately ¥3.44 billion[23]. - The basic earnings per share for 2023 was -¥2.80, compared to -¥1.88 in 2022, indicating a decline in profitability[24]. - The company reported a quarterly operating revenue of ¥313.48 million in Q4 2023, with a net loss attributable to shareholders of -¥480.64 million[26]. - The company achieved operating revenue of 1.083 billion RMB in 2023, a 40.26% increase from 772 million RMB in the previous year, primarily driven by rapid growth in sales of core products Tai'ai® (Tai'ituximab) and Aidiqi® (Vidisizumab)[33]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion in 2023, representing a 15% year-over-year growth[169]. Research and Development - The company is committed to maintaining significant R&D investments for ongoing product pipelines, which may lead to increased short-term losses[3]. - The total R&D investment for the year reached ¥1,306,306,793.92, an increase of 33.01% compared to the previous year's ¥982,080,423.23[78]. - R&D expenses accounted for 120.62% of operating revenue, a decrease of 6.57 percentage points from the previous year, primarily due to increased revenue[24]. - The company is focused on advancing multiple innovative drugs currently in critical trial phases, leading to increased R&D expenditures[24]. - The company has established three R&D centers in Yantai, Shanghai, and California, focusing on innovative biopharmaceutical development[60]. - The company has developed innovative biopharmaceutical technologies, including fusion proteins, ADCs, and bispecific antibodies, which have shown better targeting and affinity compared to traditional monoclonal antibodies[69]. - The company is actively expanding its product pipeline with several new drug candidates in various stages of clinical trials[123]. - The company is focusing on expanding its drug pipeline, particularly in the areas of autoimmune diseases and oncology[79]. Clinical Trials and Product Development - The company is actively developing innovative therapies across multiple disease treatment areas[3]. - The company submitted Investigational New Drug applications to the FDA for multiple new therapies, indicating a strong pipeline for future growth[13]. - The company has eight molecules currently in clinical development, with ongoing clinical trials for Tai'ai® and Aidiqi® in China and the United States[35]. - The company has initiated a Phase III clinical trial for Taitasip in China for the treatment of Myasthenia Gravis (MG), completing patient enrollment as of the report date[45]. - The company’s lead product, RC18 (brand name Tai'ai®), is the world's first dual-target fusion protein for treating autoimmune diseases, which received full approval in China in November 2023[43]. - The company is conducting a Phase III trial in China to evaluate Vidisicimab combined with other therapies for HER2-expressing urothelial carcinoma, with patient recruitment ongoing[50]. - The company is advancing clinical trials for several new products, including RC88, RC118, RC148, RC198, and RC248, to enhance the clinical value and potential of its pipeline[150]. Market Expansion and Strategy - The company is expanding its market presence in Asia, targeting a 30% increase in market share by 2025[15]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[164]. - The company plans to accelerate the commercialization of its core products, including Tai Tasi Pu (RC18) and Vidi Xi Tuo Monoclonal Antibody (RC48), which have been included in the national medical insurance directory[148]. - The company aims to enhance product sales through a collaborative marketing strategy that integrates medical, market, and sales efforts, focusing on academic promotion and real-world studies[64]. - The company is exploring potential acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of 2024[169]. Financial Risks and Challenges - The company’s future plans and development strategies are subject to investment risks and do not constitute substantial commitments to investors[6]. - The company faces risks related to non-profitability due to lengthy drug approval processes, which may delay product launches and impact revenue growth[88]. - The company relies on external financing for working capital, and insufficient funds could pressure its financial situation and delay R&D projects[92]. - The company faces risks related to the potential inability to include its drugs in the national medical insurance directory, which could impact future revenues[90]. Governance and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[4]. - The company’s board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[2]. - The company has not faced any significant issues regarding independence from its controlling shareholders or related parties[155]. - The company held five shareholder meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[153]. - The company has established a cash dividend policy, prioritizing cash dividends when conditions are met, with a minimum cash distribution of 10% of the distributable profit for the year[192]. Employee and Management - The company has a total of 1,308 technical personnel, 1,185 sales personnel, and 684 production personnel, indicating a strong focus on technical and sales capabilities[189]. - The company emphasizes a performance management system to distinguish high and low performers, ensuring a cycle of rewarding excellence and addressing underperformance[190]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 30.55 million RMB[173]. - The company has implemented a second phase of the H-share incentive trust plan, reflecting its commitment to employee motivation and retention strategies[186].

Financial Performance - The company's product sales revenue for the year ended December 31, 2023, was approximately RMB 1,049.2 million, representing a 42.1% increase from RMB 738.2 million in the same period last year[2]. - For the year ended December 31, 2023, the company's revenue was RMB 1,076.1 million, an increase from RMB 823.0 million[6]. - Revenue increased from RMB 767.8 million in 2022 to RMB 1,076.1 million in 2023, driven by strong sales of the autoimmune product TaiTasi and the oncology product Vidisic[31]. - The net loss increased from RMB 998.8 million in 2022 to RMB 1,511.2 million in 2023[40]. - The company reported a net loss attributable to ordinary equity holders of RMB 1,511,229,000 for 2023, compared to a loss of RMB 998,830,000 in 2022[79]. - Other income and gains decreased from RMB 232.5 million in 2022 to RMB 110.6 million in 2023, primarily due to a reduction in government subsidies by RMB 75.6 million[32]. - The company incurred a net loss of RMB 1,511.2 million for the year, compared to a net loss of RMB 998.8 million in 2022, leading to a basic loss per share of RMB 2.80, up from RMB 1.88[48]. Research and Development - The company has a robust pipeline with over ten candidate drugs in various stages of clinical development targeting multiple indications[8]. - The company initiated a Phase III clinical trial for RC28-E injection for wet age-related macular degeneration (wAMD) in China in January 2023[4]. - The company is currently conducting late-stage clinical trials for RC18 to explore its potential in treating various autoimmune diseases[9]. - The company completed a Phase III clinical trial for systemic lupus erythematosus (SLE) in China, achieving positive results and receiving full NMPA approval in November 2023[10]. - The company is conducting a Phase III trial comparing RC48 combined with chemotherapy for treating HER2-expressing locally advanced or metastatic urothelial carcinoma, with progress reported as smooth[18]. - The company has successfully renewed the inclusion of its drug in the national medical insurance catalog by the end of 2023[17]. - The company is actively assessing the potential of RC18 for treating other autoimmune diseases, although success cannot be guaranteed[15]. Regulatory Approvals - Tai'taixip received FDA approval for a Phase III clinical trial for the treatment of generalized myasthenia gravis (gMG) in January 2023, and was granted Fast Track Designation[3]. - Vidi's monoclonal antibody received NMPA approval for multiple clinical trials, including treatment for HER2-positive breast cancer and advanced solid tumors throughout 2023[4]. - RC88 received FDA approval for a Phase II IND for treating gynecological tumors in December 2023[5]. - The company received FDA approval for a global Phase III trial of the treatment for primary Sjögren's syndrome (pSS) in December 2023[13]. - The company received CDE approval in April 2023 for the Phase II IND of Vidisicimab combined with Trastuzumab injection (brand name: Tuoyi®) for HR-positive, HER2-low expressing breast cancer patients[20]. Commercialization and Market Strategy - The company has commercialized two products, RC18 (brand name: 泰愛®) and RC48 (brand name: 愛地希®), and is conducting clinical trials for over 20 indications in China and the United States[7]. - The company has established a sales and marketing department focused on the commercialization of pipeline products, with independent sales teams for autoimmune and oncology fields[28]. - The company is focused on commercializing TaiTasi and Vidisic in China while accelerating clinical trials and regulatory submissions for pipeline products[30]. - The company is expanding its market presence through targeted marketing strategies and direct interactions with key opinion leaders and physicians[28]. Financial Position and Assets - The company's bank balance and cash as of December 31, 2023, amounted to RMB 726.6 million[6]. - Total non-current assets increased to RMB 3,299.3 million as of December 31, 2023, from RMB 2,809.1 million in 2022, driven by growth in property, plant, and equipment[50]. - Current assets decreased to RMB 2,228.9 million in 2023 from RMB 3,212.1 million in 2022, with cash and cash equivalents significantly dropping to RMB 726.6 million from RMB 2,069.2 million[50]. - The company's total liabilities increased to RMB 1,137.5 million in 2023 from RMB 892.3 million in 2022, with interest-bearing bank borrowings of RMB 286.3 million reported for the first time[51]. Corporate Governance - The company has adopted corporate governance principles and has complied with all applicable codes during the fiscal year[44]. - The audit committee reviewed the financial statements and confirmed that the annual performance complies with applicable accounting standards and regulations[45]. - The financial statements are prepared in accordance with the International Financial Reporting Standards and presented in RMB[55]. Employee and Compensation - The total number of employees as of December 31, 2023, is 3,615, with total compensation costs amounting to RMB 1,152.3 million, an increase from RMB 810.7 million in 2022, primarily due to an increase in employee count and salary levels[43].

Financial Performance - The company's operating revenue for Q3 2023 was approximately ¥347 million, representing a year-on-year increase of 58.28%[4] - The net profit attributable to shareholders for Q3 2023 was approximately -¥327 million, with a year-to-date net profit of approximately -¥1.03 billion[4] - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase from RMB 569,635,902.97 in the same period of 2022, representing a growth of approximately 35%[19] - The total operating revenue for Q3 2023 was approximately $769.47 million, an increase from $569.64 million in Q3 2022, representing a growth of 35%[20] - The net profit for Q3 2023 was a loss of approximately $1.03 billion, worsening from a loss of $688.22 million in Q3 2022[20] - The total comprehensive income for Q3 2023 was approximately a loss of $1.04 billion, compared to a loss of $680.11 million in Q3 2022[21] Research and Development - R&D expenses for Q3 2023 totaled approximately ¥318 million, an increase of 49.16% compared to the same period last year[5] - The proportion of R&D expenses to operating revenue was 91.49% for Q3 2023, a decrease of 5.59 percentage points year-on-year[5] - Research and development expenses reached approximately $857.98 million in Q3 2023, compared to $662.54 million in Q3 2022, reflecting a 29.5% increase[20] Assets and Liabilities - The total assets at the end of Q3 2023 were approximately ¥5.51 billion, a decrease of 8.42% from the end of the previous year[5] - As of September 30, 2023, total current assets amounted to RMB 2,235,196,172.88, down from RMB 3,212,137,039.58 at the end of 2022, indicating a decrease of about 30%[16] - The company's total assets decreased to RMB 5,514,357,338.62 from RMB 6,021,189,680.87, reflecting a decline of about 8%[18] - Total liabilities as of September 30, 2023, were RMB 1,558,115,861.03, compared to RMB 1,040,890,051.43 at the end of 2022, indicating an increase of approximately 50%[18] - The company reported a decrease in total equity attributable to shareholders to RMB 3,956,241,477.59 from RMB 4,980,299,629.44, a decline of about 20%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,045[11] - The largest shareholder, HKSCC NOMINEES LIMITED, held 34.83% of the shares, totaling approximately 189.57 million shares[11] Cash Flow - The cash flow from operating activities for the first three quarters of 2023 was negative at approximately $1.11 billion, compared to a negative cash flow of $1.08 billion in the same period of 2022[22] - Cash inflow from investment activities in Q3 2023 totaled approximately $846.96 million, an increase from $685.65 million in Q3 2022[23] - The net cash flow from financing activities in Q3 2023 was approximately $511.63 million, a significant decrease from $2.44 billion in Q3 2022[23] - The ending cash and cash equivalents balance for Q3 2023 was approximately $546.09 million, down from $1.97 billion at the end of Q3 2022[23] Earnings Per Share - The company reported a basic and diluted earnings per share of -¥0.61 for Q3 2023[5] - Basic and diluted earnings per share for Q3 2023 were both -1.91 yuan, compared to -1.32 yuan in Q3 2022[21]

Financial Performance - The company's operating revenue for Q3 2023 was approximately CNY 347.04 million, representing a year-on-year increase of 58.28%[6]. - The net profit attributable to shareholders for Q3 2023 was a loss of CNY 327.23 million, with a cumulative loss of CNY 1.03 billion for the year-to-date[6]. - Total operating revenue for the first three quarters of 2023 reached RMB 769,470,314.65, a significant increase of 35% compared to RMB 569,635,902.97 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was a loss of RMB 1,030,585,859.60, worsening from a loss of RMB 688,219,233.92 in the same period of 2022[21]. - The company experienced a total comprehensive loss of RMB 1,038,494,630.57 in 2023, compared to a loss of RMB 680,108,752.02 in 2022[22]. Research and Development - Research and development expenses totaled CNY 317.52 million in Q3 2023, an increase of 49.16% compared to the same period last year[7]. - The ratio of R&D expenses to operating revenue was 91.49%, a decrease of 5.59 percentage points year-on-year[7]. - The company continues to invest heavily in R&D to support its drug pipeline and clinical trials, leading to increased operational costs[12]. - Research and development expenses increased to RMB 857,977,852.40 in 2023, compared to RMB 662,541,383.59 in 2022, marking a 29.5% rise[21]. Assets and Liabilities - Total assets at the end of Q3 2023 were approximately CNY 5.51 billion, down 8.42% from the end of the previous year[7]. - The equity attributable to shareholders decreased by 20.56% year-on-year, amounting to approximately CNY 3.96 billion[7]. - The company's total assets as of September 30, 2023, amount to ¥5,514,357,338.62, a decrease from ¥6,021,189,680.87 at the end of 2022[19]. - Current assets total ¥2,235,196,172.88, down from ¥3,212,137,039.58 in the previous year[18]. - The total liabilities as of September 30, 2023, are ¥1,558,115,861.03, compared to ¥1,040,890,051.43 in the previous year[19]. Cash Flow - The company reported a net cash flow from operating activities of CNY -1.11 billion for the year-to-date[7]. - Cash flow from operating activities showed a net outflow of RMB 1,114,762,180.68 in 2023, compared to a net outflow of RMB 1,080,292,854.28 in 2022[23]. - Cash inflow from investment activities totaled RMB 846,955,292.55 in 2023, while cash outflow was RMB 1,767,323,954.74, resulting in a net outflow of RMB 920,368,662.19[24]. - The company reported cash and cash equivalents at the end of Q3 2023 amounting to RMB 546,094,957.35, down from RMB 1,967,108,319.61 at the end of Q3 2022[24]. - The company has a total of ¥609,013,239.33 in cash and cash equivalents, down from ¥2,187,326,306.04[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,045[13]. - HKSCC NOMINEES LIMITED holds 189,566,228 shares, accounting for 34.83% of total shares[14]. Market Strategy - The increase in operating revenue was primarily driven by higher sales of injectable drugs, including TaiTasi and VidiXimab[11]. - The company is focusing on expanding its market presence and developing new products and technologies[16].

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 419,073 thousand, representing an increase of 20.1% compared to RMB 348,779 thousand for the same period in 2022[8]. - Gross profit for the first half of 2023 was RMB 316,418 thousand, up from RMB 181,274 thousand in the same period of 2022, indicating a significant improvement in profitability[8]. - The company reported a pre-tax loss of RMB 703,362 thousand for the first half of 2023, compared to a loss of RMB 489,126 thousand in the same period of 2022[8]. - The net loss for the period was RMB 703,362 thousand, compared to a net loss of RMB 489,126 thousand in the previous year, indicating a 43.8% increase in losses[104]. - The company reported a basic loss per share of RMB 1.30 for the period, compared to RMB 0.96 in the same period last year[104]. - The company's total comprehensive loss for the period was RMB 709,024 thousand, compared to a loss of RMB 486,630 thousand in the previous year[108]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 5,831,113 thousand, a decrease from RMB 6,021,191 thousand as of December 31, 2022[8]. - Total liabilities as of June 30, 2023, were RMB 1,535,961 thousand, an increase from RMB 1,040,891 thousand as of December 31, 2022[8]. - The total equity as of June 30, 2023, was RMB 4,295,152 thousand, down from RMB 4,980,300 thousand as of December 31, 2022[8]. - The company's total current assets decreased to RMB 1,264,418,000 as of June 30, 2023, from RMB 2,187,942,000 at the end of 2022[133]. - The company's cash and cash equivalents decreased to RMB 1,119,661 thousand as of June 30, 2023, down from RMB 2,069,180 thousand at the end of 2022[133]. Research and Development - Research and development expenses increased to RMB 540,453 thousand in the first half of 2023, compared to RMB 449,672 thousand in the same period of 2022, reflecting the company's commitment to innovation[8]. - The company is conducting late-stage clinical trials for its proprietary drug, RC18 (brand name: Tai'ai®), targeting eight autoimmune diseases[12]. - The company has over ten drug candidates in its pipeline, with seven in clinical development targeting more than twenty indications[9]. - The company is focusing on the development of its lead antibody-drug conjugate (ADC), RC48, for treating HER2-expressing solid tumors, with multiple late-stage clinical trials ongoing in China[22]. Market and Product Development - The company aims to become a leading player in the global biopharmaceutical industry, focusing on innovative biologics for unmet medical needs[9]. - The commercialization team for autoimmune products has gained access to over 600 hospitals as of June 30, 2023, following the inclusion of Taitasip in the national medical insurance catalog[35]. - Revenue from the Chinese market was RMB 416,118 thousand, up 26.5% from RMB 328,668 thousand in 2022[123]. - The company plans to launch two new products by the end of 2023, targeting a market expansion of 15% in the oncology sector[173]. Shareholder and Equity Structure - As of June 30, 2023, the company’s total shares outstanding are 544,263,003, including 354,681,764 A-shares and 189,581,239 H-shares[2]. - Major shareholders include RongChang Holding Group LTD., which holds approximately 53.20% of A shares and 12.79% of H shares, reflecting significant control over the company[66]. - The company has granted restricted shares under the 2022 A-share incentive plan to several executives, indicating a commitment to align management interests with shareholder value[64]. - The ownership structure suggests potential stability in management decisions, as major shareholders are also involved in the company's strategic direction[63]. Financial Management and Governance - The independent auditor, Ernst & Young, reviewed the interim financial information and found it compliant with applicable accounting standards and regulations[97]. - The company has adopted the corporate governance code and has complied with all applicable code provisions during the reporting period[95]. - The company confirmed that all directors and supervisors complied with the standard code of conduct for securities trading during the reporting period[96]. - The company did not declare or pay any dividends for the six months ended June 30, 2023, consistent with the previous year[128]. Future Outlook - The company plans to utilize all remaining unutilized proceeds by December 31, 2023, based on the best estimates of future market conditions[54]. - The company has set a revenue guidance of RMB 1 billion for the full year 2023, indicating a growth target of 20%[173]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[173]. - The company anticipates a positive outlook for the next fiscal year, driven by strong user engagement and innovative product offerings[81].

[Supplemental Announcement to the 2022 Annual Report](index=1&type=section&id=Supplemental%20Announcement%20to%20the%202022%20Annual%20Report) This announcement provides supplementary information to RemeGen Co., Ltd.'s 2022 annual report, detailing awards granted under H-share and A-share schemes and confirming the unchanged status of other annual report content [Details of Awards Granted Under H-share Scheme](index=2&type=section&id=Details%20of%20Awards%20Granted%20Under%20H-share%20Scheme) This section details awards granted under the H-share scheme to directors, the five highest-paid individuals, and other employees, including grant quantities, purchase prices, vesting, and forfeiture Overview of H-share Scheme Awards (As of December 31, 2022) | Grantee Category | Grantee Name | Granted Quantity (Shares) | Purchase Price (HKD) | Vested During Reporting Period (Shares) | Forfeited During Reporting Period (Shares) | Remaining as of Dec 31, 2022 (Shares) | | :--------------- | :----------- | :------------------------ | :------------------- | :-------------------------------------- | :-------------------------------------- | :------------------------------------ | | Executive Director | Fang Jianmin | 1,500,000 | 27.06 | 0 | 0 | 1,500,000 | | Executive Director | He Ruyi | 1,600,000 | 16.91 | 0 | 0 | 1,600,000 | | Five Highest-Paid Individuals | Subtotal | 500,000 | - | 137,500 | 212,500 | 150,000 | | Other Employees | Subtotal | 1,788,380 | - | 197,500 | 228,750 | 1,362,130 | - The exercise period for all H-share awards is **eight years**[2](index=2&type=chunk) [Details of Awards Granted Under A-share Scheme](index=3&type=section&id=Details%20of%20Awards%20Granted%20Under%20A-share%20Scheme) This section provides specific information on awards granted under the A-share scheme to directors, senior management, major shareholders and their associates, and other employees, including grant quantities, grant prices, and vesting periods Overview of A-share Scheme Awards (As of December 31, 2022) | Grantee Category | Grantee Name | Granted Quantity (Shares) | Grant Price (RMB) | Average Closing Price Immediately Prior to Grant Date (RMB) | Remaining as of Dec 31, 2022 (Shares) | | :--------------- | :----------- | :------------------------ | :---------------- | :---------------------------------------------------------- | :------------------------------------ | | Executive Director | Wang Weidong | 350,000 | 36.36 | 75.05 | 350,000 | | Executive Director | He Ruyi | 24,200 | 36.36 | 75.05 | 24,200 | | Executive Director | Lin Jian | 14,850 | 36.36 | 75.05 | 14,850 | | Other Senior Management, Major Shareholders & Employees | Subtotal | 2,480,400 | 36.36 | 75.05 | 2,465,550 | - All A-share awards were granted on December 28, 2022, with a vesting period extending to December 27, 2028[3](index=3&type=chunk) [Other Information](index=3&type=section&id=Other%20Information) This section includes the announcement publication date and board composition as of that date, reaffirming that all other information and content of the 2022 annual report remain unchanged - This supplemental announcement was published on **September 11, 2023**[4](index=4&type=chunk) - As of the announcement date, the board of directors comprises **4 executive directors, 2 non-executive directors, and 3 independent non-executive directors**[4](index=4&type=chunk) - Except for the supplementary information disclosed in this announcement, all other information and content of the 2022 annual report remain unchanged[3](index=3&type=chunk)